Core Insights - The core viewpoint of the news is that the Bozhou Traditional Chinese Medicine Commodity Trading Center has officially released its 2026 operational plan, focusing on brand leadership and a "1+5" development strategy to ensure sustained growth in performance for 2026 [1] Group 1: Brand Strategy - The trading center will elevate brand building to a strategic core, aiming to enhance the recognition and influence of the "BoJiao" brand in the traditional Chinese medicine industry through integrated marketing and multi-dimensional communication [1] - The center plans to develop the "Shen Nong Zhou Ben Cao Zhen Xuan" IP, enhancing content e-commerce and live streaming operations to create a closed loop of "content-fans-transaction" to empower physical merchants and explore new growth channels [1] Group 2: Business Segments - The trading center will upgrade five main business segments to form a solid support for development, including: - **Herb Procurement Business**: Focused on reducing procurement costs and stabilizing the supply chain through strategic partnerships with core clients like Jiuzhou Fangyuan, aiming to establish a quality-controlled and traceable supply system [2] - **Bulk Trading Business**: Transitioning from "transaction matching" to "ecological service provider," focusing on building services, increasing platform traffic, and creating a professional B2B e-commerce platform for traditional Chinese medicine [2] - **Fresh Processing Business**: Collaborating closely with strategic partner Jiuzhou Fangyuan to expand the fresh processing industry chain, integrating upstream processing capacity through acquisitions and controlling core raw material resources [2] Group 3: Market Operations - The offline market operations will aim to increase profitability and stabilize merchant recruitment, with specific goals including ensuring rental income, raising the occupancy rate to over 95%, and optimizing market image through standardized practices [3] - The warehousing business will shift from passive rent collection to active management and profit center development, expanding value-added services such as third-party regulatory warehousing and supply chain finance [3] Group 4: Strategic Framework - The introduction of the "1+5" strategic system marks a new phase for the Bozhou Traditional Chinese Medicine Commodity Trading Center, emphasizing brand value, deep collaboration among five business segments, and the integration of online and offline operations [3] - The center aims to leverage its existing advantages in resource integration, platform operation, and industry chain services to respond to trends in standardization, digitalization, and integration, providing more efficient, transparent, and valuable services to clients in the industry [3]

Core Viewpoint - The traditional Chinese medicine company Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd. has reported its first loss in ten years, highlighting the challenges faced by the industry during a significant transformation period [2][4]. Financial Performance - Zhenbaodao expects a net profit loss of approximately -1.173 billion to -1.012 billion yuan for the fiscal year 2025, marking a dramatic shift from profit to loss compared to the previous year [2]. - The company's net profit has decreased by 330.94% to 367.68% year-on-year, setting a record for the worst performance in its history [2]. - In the first half of 2025, the company's revenue plummeted by 57.04% to 713 million yuan, with a net loss of 78.29 million yuan, a 119.9% decline year-on-year [6]. Market Challenges - The decline in performance is attributed to several factors, including lower-than-expected sales of core products, price reductions, and significant credit impairment losses of approximately 395 million yuan [4][6]. - The company’s core products, which account for over 70% of its revenue, have been affected by national procurement policies and ongoing healthcare cost controls [4][5]. Strategic Issues - Zhenbaodao's heavy reliance on traditional products and slow innovation has led to strategic difficulties, forcing the company to drastically cut sales and R&D expenses to maintain cash flow [4][6]. - The company’s R&D expenditure has significantly decreased by 52.64% to 37.99 million yuan, representing only 2.60% of its revenue, which is well below the industry average [7]. Governance Concerns - The company faced criticism from the Shanghai Stock Exchange for a 425 million yuan equity transfer that bypassed required approval processes, raising governance concerns [8][9]. - Despite the financial downturn, Zhenbaodao continued to distribute dividends totaling 141 million yuan in 2024, leading to market skepticism regarding the management's priorities and potential wealth transfer to major shareholders [9]. Industry Outlook - The significant loss signals a broader trend where traditional Chinese medicine companies relying on single products and inefficient operations may struggle to survive as procurement practices become more standardized [10]. - Zhenbaodao is attempting to adjust its strategy by focusing on innovation in traditional Chinese medicine, biopharmaceuticals, and chemical drugs, while also restructuring its marketing approach [10].

登录新浪财经APP 搜索【信披】查看更多考评等级 重要内容提示： ■ 一、信息披露义务人及其一致行动人的基本信息 1.身份类别 ■ 证券代码：603567证券简称：珍宝岛公告编号：临2026-009 黑龙江珍宝岛药业股份有限公司 关于控股股东权益变动触及1%刻度的提示性公告 黑龙江创达集团有限公司保证向本公司提供的信息真实、准确、完整，没有虚假记载、误导性陈述或重 大遗漏。 本公司董事会及全体董事保证公告内容与信息披露义务人提供的信息一致。 2.信息披露义务人信息 ■ 3.一致行动人信息 上述信息披露义务人无一致行动人。 二、权益变动触及1%刻度的基本情况 黑龙江珍宝岛药业股份有限公司(以下简称"公司")于2026年2月5日收到公司控股股东黑龙江创达集团有 限公司（以下简称"创达集团"）的通知,获悉创达集团发行的2023年面向专业投资者非公开发行可交换 公司债券（第一期）和2023年面向专业投资者非公开发行可交换公司债券（第二期）的债券持有人于 2026年1月13日-2026年2月4日发生换股10,511,854股，导致创达集团持股比例被动下降，持有公司股份 比例从56.98%减少至55.86%，权益变动触及 ...

证券代码：603567 证券简称：珍宝岛 公告编号：临2026-009 一、 信息披露义务人及其一致行动人的基本信息 1.身份类别 | | ☑控股股东/实际控制人及其一致行动人 □其他 5%以上大股东及其一致行动人 | | --- | --- | | 投资者及其一致行动人的身份 | □合并口径第一大股东及其一致行动人（仅适用 | | | 于无控股股东、实际控制人） | | | □其他______________ | 2.信息披露义务人信息 | 信息披露义 务人名称 | | 投资者身份 | 统一社会信用代码 | 住所 | | --- | --- | --- | --- | --- | | | 控股股东/实控人 ☑ | | | 虎 林 市 解 放 西 | | 黑龙江创达 | | | | | | 集团有限公 | □ 控股股东/实控人 | | ☑9123038156060139X7 | 街 北 检 察 院 东 | | | 的一致行动人 | | | 侧宝润香里 1 号 | | 司 | □ 其他直接持股股 | | □ 不适用 | 楼 1 号门市 | | | 东 | | | | 黑龙江珍宝岛药业股份有限公司 关于控股股东权 ...

证券代码：603567 证券简称：珍宝岛 公告编号：临 2026-008 公司控股股东创达集团 2023 年面向专业投资者非公开发行可交换公司债券 （第二期）已发行完毕，目前进入换股期。为了保障"23 创 02EB"债券持有人 利益，创达集团决定将换股价格向下修正。 黑龙江珍宝岛药业股份有限公司 关于控股股东非公开发行可交换公司债券 换股价格调整的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，黑龙江珍宝岛药业股份有限公司（以下简称"公司"）收到公司控股 股东黑龙江创达集团有限公司（以下简称"创达集团"）的通知，创达集团 2023 年面向专业投资者非公开发行可交换公司债券（第二期）（以下简称"本期可交 债"）换股价格将进行调整，现将有关事项公告如下： 一、控股股东可交换公司债券的基本情况 公司控股股东创达集团已于 2023 年 6 月 28 日完成本期可交债的发行。本期 可交债简称"23 创 02EB"，债券代码为"137177"，发行规模 0.9 亿元，债券期 限 3 年。具体内容详见公司于 2023 年 ...

Summary of Key Points Core Viewpoint - On February 4, a block trade of 1.36 million shares of Zhenbao Island was executed, amounting to 10.5264 million yuan, which accounted for 8.46% of the total trading volume for the day. The transaction price was 7.74 yuan, representing a discount of 10.31% compared to the market closing price of 8.63 yuan [1]. Group 1 - The block trade involved a total of 1.36 million shares of Zhenbao Island [1]. - The total transaction value for the block trade was 10.5264 million yuan [1]. - The transaction price of 7.74 yuan was 10.31% lower than the market closing price of 8.63 yuan [1]. Group 2 - The block trade occurred on February 4, 2026 [2]. - Multiple brokerage firms participated in the trade, with varying transaction amounts and volumes [2]. - The trading volume for the block trade was 136,000 shares, with specific amounts allocated to different brokerage firms [2].

Core Viewpoint - The announcement details the plan of Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd.'s controlling shareholder, Heilongjiang Chuangda Group Co., Ltd., to supplement the pledge of shares to secure the repayment of bonds and facilitate share exchanges [2][3]. Group 1: Share Pledge Details - As of February 2, 2026, Chuangda Group holds 530,561,726 shares of the company, accounting for 56.38% of the total share capital, with 427,276,426 shares pledged, representing 80.53% of its holdings [2]. - Chuangda Group plans to pledge an additional 1,170,000 shares (0.12% of total share capital, 0.22% of its holdings) to secure the repayment of the second phase of the non-public exchangeable bonds (23 Chuang02EB) [2][3]. - After the completion of this pledge, the total number of pledged shares will increase to 428,446,426, which is 80.75% of Chuangda Group's holdings [3]. Group 2: Financial and Operational Status - Chuangda Group has no controlling persons and has not engaged in any actions that would harm the interests of the listed company, such as non-operational fund occupation or illegal guarantees [7]. - The pledge will not adversely affect the company's main business or operational capabilities, nor will it lead to changes in control [7]. - Chuangda Group's financial health is stable, with no significant litigation or arbitration related to debt issues, and it has sufficient repayment capabilities through operational cash flow and dividends from subsidiaries [11][12].

证券日报网讯 2月3日，珍宝岛（603567）在互动平台回答投资者提问时表示，目前公司生产经营活动 正常开展，不存在网络所述的长期拖欠员工薪资情形。 ...

Core Viewpoint - The pharmaceutical sector is experiencing a mixed performance in 2025, with a significant number of companies forecasting profit increases, while others are facing substantial losses. Group 1: Profit Forecasts - A total of 283 pharmaceutical stocks have disclosed their 2025 earnings forecasts, with 160 companies expecting year-on-year profit growth. Among these, Sino Medical has the highest projected increase, with an expected profit growth of over 32 times [1][4]. - WuXi AppTec is anticipated to achieve a record net profit of 19.15 billion yuan, marking the highest since its listing. This includes nearly 5.6 billion yuan in non-recurring gains from the sale of equity interests [6]. - Sino Medical's projected net profit for 2025 is between 43 million and 50 million yuan, reflecting a year-on-year increase of 2,767% to 3,233%. The growth is attributed to stable revenue from its neuro-interventional business and a 22% increase in its coronary intervention business due to the implementation of a national procurement policy [4][5]. Group 2: Loss Forecasts - Over 120 companies are forecasting profit declines for 2025, with 39 facing their first losses since going public, including companies like Zhifei Biological and Zhenbao Island. Zhifei is expected to report a loss of between 10.698 billion and 13.726 billion yuan, a decline of 630% to 780% compared to the previous year [2][8]. - Zhenbao Island anticipates a net loss of between 1.012 billion and 1.173 billion yuan, attributed to delays in the procurement process and increased cost control measures [8]. - Huiyu Pharmaceutical's losses are primarily due to non-core investment losses, with a fair value loss of 173 million yuan from its investment in Zhejiang Tongyuan Kang Pharmaceutical [9]. Group 3: Innovative Drug Companies - The innovative drug sector is showing signs of recovery, with companies like Nocera and Rongchang Biopharma expected to turn losses into profits. Nocera forecasts a net profit of approximately 633 million yuan, a significant increase from the previous year [3][11]. - Rongchang Biopharma is also expected to achieve profitability with projected revenues of around 3.25 billion yuan, a year-on-year increase of about 89% [11]. - Companies like Junshi Biosciences are reducing their losses significantly, with an expected net loss of around 873 million yuan, a reduction of 408 million yuan compared to the previous year [11][12].

证券代码：603567 证券简称：珍宝岛 公告编号：临 2026-007 黑龙江珍宝岛药业股份有限公司 关于控股股东拟办理非公开发行可交换公司债券 股份补充质押的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 截至 2026 年 2 月 2 日，黑龙江珍宝岛药业股份有限公司（以下简称"公 司"）控股股东黑龙江创达集团有限公司（以下简称"创达集团"）持有公司股份 530,561,726 股，占公司总股本的 56.38%，其累计质押公司股份数量 427,276,426 股，占所持公司股份数量的 80.53%，无一致行动人。 ● 创达集团拟将持有的 1,170,000 股公司股份（占公司总股本的 0.12%， 占创达集团所持公司股份数量的 0.22%）办理补充质押，用于对债券持有人交换 股份和黑龙江创达集团有限公司-2023 年面向专业投资者非公开发行可交换公 司债券（第二期）（以下简称"23 创 02EB"）本息偿付提供担保。 ● 本次补充质押登记办理完成后，创达集团累计质押公司股份数量为 428, ...